WO1997029745A1 - Zwitterionic compositions and methods as biological response modifiers - Google Patents
Zwitterionic compositions and methods as biological response modifiers Download PDFInfo
- Publication number
- WO1997029745A1 WO1997029745A1 PCT/US1997/002270 US9702270W WO9729745A1 WO 1997029745 A1 WO1997029745 A1 WO 1997029745A1 US 9702270 W US9702270 W US 9702270W WO 9729745 A1 WO9729745 A1 WO 9729745A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- zwitterion
- hepes
- group
- acid
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims description 71
- 239000000367 immunologic factor Substances 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 31
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 77
- 239000007995 HEPES buffer Substances 0.000 claims description 75
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 210000002966 serum Anatomy 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 16
- 230000008512 biological response Effects 0.000 claims description 13
- 239000003607 modifier Substances 0.000 claims description 13
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 239000007990 PIPES buffer Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000007987 MES buffer Substances 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 239000007991 ACES buffer Substances 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 49
- 238000004113 cell culture Methods 0.000 description 23
- 208000002193 Pain Diseases 0.000 description 22
- 208000023275 Autoimmune disease Diseases 0.000 description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 229930182816 L-glutamine Natural products 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 230000007423 decrease Effects 0.000 description 14
- -1 aliphatic heterocyclic compounds Chemical class 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 208000036142 Viral infection Diseases 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000009385 viral infection Effects 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000001991 pathophysiological effect Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 8
- 206010058019 Cancer Pain Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 230000002607 hemopoietic effect Effects 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 208000007766 Kaposi sarcoma Diseases 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 5
- 102000002852 Vasopressins Human genes 0.000 description 5
- 108010004977 Vasopressins Proteins 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 206010028417 myasthenia gravis Diseases 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229960003726 vasopressin Drugs 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229940080861 demerol Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000003701 histiocyte Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000035943 Aphagia Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000003102 mental depression Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000005549 size reduction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 239000007988 ADA buffer Substances 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 206010056557 Gulf war syndrome Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TUDKHASXBPBVOK-VGHSCWAPSA-N [(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;n-(4-hydroxyphenyl)acetamide;naphthalene-2-sulfonic acid Chemical compound CC(=O)NC1=CC=C(O)C=C1.C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 TUDKHASXBPBVOK-VGHSCWAPSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical group O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 229940099212 dilaudid Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001831 immunophysiological effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000010076 persian gulf syndrome Diseases 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- autoimmune disorders There are many diseases associated with autoimmune disorders. Rheumatoid arthritis and myasthenia gravis are examples. The etiology of many autoimmune diseases is not clear. Genetic and/or environmental aspects may contribute in several ways to alter hemopoietic and immune responses. Certain drugs may trigger autoimmune responses as well as induce immunosuppressed states.
- the present invention relates to a method for the treatment of diseases in mammals by the administration of zwitterionic compositions as safe and effective biological response modifiers to the mammals and to the zwitterionic compositions used and the preparation of such zwitterionic compositions for use in treatment.
- Zwitterionic molecules have a definitive effect as a biological response modifier (BRM).
- Zwitterionic molecules are substances that have neither a negative nor a positive charge.
- Zwitterions are compounds having a net charge on the molecule which is zero and which have positive and negative groups that are equally ionized in the molecule, and are dipolar molecules containing, for example, hydroxy groups and amino groups and also acid groups, like phosphoric, carboxylic or sulfonic acid groups, and, for example, generally having pK a in the range of 6.15 to 8.4.
- a number of zwitterion compounds may be employed in the treatment of mammal diseases as active ingredients, either alone or in various combinations, and typically in combination with one or more solid or liquid pharmaceutically acceptable carrier materials.
- zwitterion compounds are recognized and used as buffers and not used or recognized as active ingredients in the treatment of diseases, such as the HEPES, PIPES, etc. compounds and the salts thereof.
- Some zwitterion compounds of the invention are set forth in the following table:
- the zwitterion compounds of the table are characterized by one or two nitrogen-carbon bonds, either as aliphatic heterocyclic compounds or aliphatic compounds usually with an acid group (COO " or S0 3 " ) and an alkaline group (OH or N + , NH and NH 2 ) .
- One preferred zwitterion compound group as PIPES and HEPES comprises six membered heterocyclic rings with two nitrogen at each end and connected with divalent alkylidenes, like -CH 2 - divalent radical, while MES is a heterocyclic compound with both oxygen and nitrogen in the ring with the NH group connected by - CH 2 -)-structure ⁇ . ⁇ to an acid group.
- MES divalent alkylidenes
- MES is a heterocyclic compound with both oxygen and nitrogen in the ring with the NH group connected by - CH 2 -)-structure ⁇ . ⁇ to an acid group.
- R x and R 2 represent a - CH 2 -)-êt x _ 3 , or R x is a nitrogen or oxygen as a part of a 5-6 member heterocyclic ring with N + or N + H as part of the ring, or where R x includes a nitrogen connected directly to -f CH 2 - i. x _ 3 , which alkylidene is connected to an alkaline group, like NH 2 or OH group.
- the zwitterion compounds and their respective pharmaceutically acceptable salts which are preferred include HEPES, PIPES, MES, ADA and ACES, alone or in therapeutic combinations.
- amphoteric zwitterion compounds may be employed as active ingredients with other active ingredients, as well as other components and carriers typically used in pharmaceutical compositions; such as, but not limited to: buffers, stabilizers, dyes, antioxidants, dispersing agents, fillers, surfactants, silicones, bulking agents, pigments, salts, human or animal (natural or synthetic) cells and cellular components, antibiotics, drugs, vitamins, amino acids, proteins, serum and various other compounds and combinations thereof in varying amounts.
- HEPES and PIPES to provide macrophage infiltration of cancer tumors in dogs, and thus to provide an antitumor effect in the treatment of various diseases, and further demonstrate immune stimulating capabilities as evidenced in tests by the production of giant platelets and histiocytes.
- the dose schedule of zwitterion compounds as biologic response modifiers may vary depending on the disease and condition, but for treatment may range from about O.lmg/kg to 5000mg/kg.
- One amphoteric zwitterion compound useful in the invention comprises inhibited piperazine zwitterionic compounds, such as, but not limited to, an N-2 hydroxyl or amino alkyl piperazine-N-2 alkane acid, like carboxylic acid, phosphoric or sulfonic acid and its effective, non-toxic salts and derivatives and substituents.
- piperazine zwitterionic compounds such as, but not limited to, an N-2 hydroxyl or amino alkyl piperazine-N-2 alkane acid, like carboxylic acid, phosphoric or sulfonic acid and its effective, non-toxic salts and derivatives and substituents.
- HEPES a zwitterion known as HEPES and its acid salts
- N-2 Hydroxyethylpiperazine-N'-2 Ethane Sulfonic Acid formula weight 238 (i.e. C 2 H 18 N 2 0 4 S) (HEPES). They have routinely been used in cell cultures as a buffer and, to date, were not suspected to have any effects on cells, physiologic pathways or disease processes.
- HEPES and other zwitterionic compounds are true biological response modifiers (BRM). They effect positive changes in cancer, cancer pain, autoimmune disease and viral infections and toxic syndromes. They can be used alone and/or in combination with mammalian serum and/or in combination with cell culture supernatants utilizing mammalian serum. There appears to be a possible interaction with serum and/or cell culture supernatants.
- the bioactive pathways may be affected by various compositions of zwitterionic molecules. It remains clear that they can play a role as a biological response modifier alone or in combinations.
- the mechanisms of action may be singular or multiple involving physiological, pathophysiological and immunological pathways. There may be effects of activating and/or stimulating and/or blocking specialized pathways and/or specialized receptor sites. There is a positive effect on the hemopoietic system. There appears to be effects on cell product secretion of many forms. These effects are beyond that of buffering capacity as evidenced by the effect on disease processes.
- Membrane stabilization may play an important role in causing abnormal cell division and abnormal cell function to normalize, either by external physiogenic factors or internal cellular functions, or both. In any event, this first description of the unique abilities of HEPES as a zwitterionic molecule and the effect upon disease processes is submitted.
- the present invention relates to methods and compositions for inducing antitumor activity, tumor volume reduction, reduction of pain in cancer patients, induction of anti-inflammatory response in autoimmune-mediated disease, reduction of the activity and progression of immunologically-mediated diseases, induction of the regression of tumor growth, induction of the regression of autoimmune activity in immunologically-mediated disease and antiviral effects.
- the invention shows a unique capability for inducing certain biochemical, physiological and immunological responses that cause lysis and/or necrosis of tumors and slowing the progression of diseases, including cancer, autoimmune disease and diseases caused by viral infection.
- HEPES N-2 Hydroxyethylpiperazine-N'-2 Ethane Sulfonic Acid
- HEPES N-2 Hydroxyethylpiperazine-N'-2 Ethane Sulfonic Acid
- HEPES appears to have an effect on cell culture immunological characteristics that are unique and not directly related to its buffering capability.
- the present invention provides an effective treatment that is relatively non-toxic and safe. Its individual uniqueness is shown in many ways. For years, HEPES, a zwitterionic molecule, has been used as a buffer in mammalian cell cultures. It was not believed to have any specialized effects on cells. Certainly, it has not been viewed as an independent agent to treat cancer, cancer pain, autoimmune disease or certain infectious states. It is now shown that HEPES (C 5 H 18 N 2 0 4 S) (N-2 Hydroxyethylpiperazine-N , -2 Ethane Sulfonic Acid) and its homologs and analogs can, in certain preparations, have antitumorgenic effects on tumor growth, volume reduction, tumor activity and cancer pain.
- HEPES C 5 H 18 N 2 0 4 S
- HEPES N-2 Hydroxyethylpiperazine-N , -2 Ethane Sulfonic Acid
- HEPES has been used as a buffer in cell culture technology. The invention became apparent when use of HEPES and human serum without cell culture was given as a control to patients who were intended to receive certain cell culture supernatants for experimental treatment of cancer, cancer pain and immune disease and viral infections.
- HEPES is an immunological activator by itself. This would categorize HEPES as a true biological response modifier (BRM) .
- the present invention provides a method of preparing zwitterionic compositions for administration to a subject and the use of same compositions for the treatment of cancer, cancer pain, autoimmune diseases and infectious diseases.
- the compositions used for administration comprise: a) preparing certain concentrations of HEPES in solutions alone and/or with amino acids and/or L- glutamine and/or with bicarbonate; b) preparing certain concentrations of HEPES in solutions with amino acids and/or L-glutamine and/or bicarbonate and/or human serum; and c) preparing certain concentrations of HEPES in solutions with amino acids and/or L-glutamine and/or bicarbonate and/or human serum and combining same with mammalian cell cultures, whether same cells in culture are transformed or not transformed, and using the supernatant and/or fractions of the supernatant alone or in combination to potentiate cellular production of immunological substances that are effective in working as biological response modifiers alone or in combination with zwitterionic compounds.
- the invention also provides a method of activating the immune system of a subject, comprising the above compositions when administered in an amount of the claimed compositions such that the immune system is activated. "Activating” can include activating, for example, a stimulator or blocker of immune activity.
- CD 2 , CD 3 CD ⁇ , and CD 20 counts and increases in stem cell production in subjects who are healthy or immunosuppressed comprising administration of a zwitterionic molecule, like HEPES, in compositions as described that effect increases in certain hemopoietic mechanisms.
- a zwitterionic molecule like HEPES
- Also provided is a method of reducing tumor size and/or volume comprising administrating to the subject a composition containing HEPES, a zwitterionic molecule, in a tumor-reducing amount, compositions such that tumor size and/or tumor volume is reduced. Further, that the induction of tumor lysis and/or necrosis occurs due to the biological response modifier effect of HEPES as a zwitterionic compound.
- the present invention provides a method of treating autoimmune diseases in a subject, comprising administering to the subject an amount of the compositions containing HEPES, a zwitterionic molecule, such that the progression of the autoimmune disease is slowed and/or reversed, the effect of which is due to HEPES as a biological response modifier. Also provided are methods of treating pain due to inflammation and/or tumor activity and/or autoimmune disease activity comprised of administering an amount and certain compositions containing a zwitterionic molecule, like HEPES or PIPES, to the subject.
- kits for treating viral infections in a subject comprising of administering an amount of the zwitterion compositions as the active ingredient resulting in a decrease of viral activity.
- the present invention provides methods of preparing solutions containing amphoteric zwitterion compounds, like HEPES, as: a) the active ingredient in solutions with HEPES and/or amino acids and/or L-glutamine and/or bicarbonate; b) the active and/or activating agent in solutions containing HEPES and/or amino acids and/or L-glutamine and/or bicarbonate and/or mammalian (human) serum; and c) HEPES and/or amino acids and/or L-glutamine and/or bicarbonate and/or human serum and/or human (mammalian) serum in cell culture.
- Cells used in cell culture preparations were human B lymphoid cells from a healthy donor.
- Epstein-Barr virus The cells had been transformed or activated by prior exposure to Epstein-Barr virus (EBV) which is confirmed by the presence of Epstein-Barr virus nucleic antigen (EBNA). Approximately sixty percent (60%) of the human population is Epstein-Barr virus nucleic antigen positive.
- Epstein-Barr virus nucleic antigen positive There are other methods for cell activation, such as endotoxin stimulation and protein activation stimulation (PAS) techniques, which are known to those of skill in the art.
- PAS protein activation stimulation
- the cells used are IgM secreting, and this is not considered a limiting factor.
- the preparations containing HEPES in cell culture may be further combined by the presence of HEPES in terms of immunologically activating and/or stimulating and/or blocking effects of other cell secreted substances.
- HEPES The effects on cancer, cancer pain, autoimmune diseases and viral infections may be increased further by HEPES. It may be that the action of HEPES as a biological response modifier may be enhanced by the presence of certain substances secreted by cells in culture and/or HEPES or the substances may have synergism in activity and/or certain immunological pathways are activated, stimulated or blocked when HEPES is added to cell cultures due to one or more immunophysiological pathway actions. It is further acknowledged that additional and/or the same mechanisms are present when HEPES is combined with human serum.
- the serum may contain certain imraunologically active substances that when combined with HEPES are potentiated and/or certain substances when combined with HEPES cause activation and/or stimulation and/or blocking of specialized pathways.
- HEPES a biological response modifier, used alone or in various compositions, or other zwitterionic molecules, has shown effectiveness by positive indicators, such as, for example, tumor lysis and/or necrosis; decrease in the number and/or distribution of lesions; decrease in tumor size and/or volume; decrease in tumor markers; decrease in pain and/or analgesic usage; increase in immunological and hemopoietic markers; decrease in inflammation and markers associated with inflammatory processes; decrease in total viral loads; and decreases in auto antibody production in immune-mediated disease.
- positive indicators such as, for example, tumor lysis and/or necrosis; decrease in the number and/or distribution of lesions; decrease in tumor size and/or volume; decrease in tumor markers; decrease in pain and/or analgesic usage; increase in immunological and hemopoietic markers; decrease in inflammation and markers associated with inflammatory processes; decrease in total viral loads; and decreases in auto antibody production in immune-mediated disease.
- the present invention provides a method for activating or enhancing the immune system by stimulating and/or blocking and/or other i munophysiologic pathway effects consistent with a BRM, comprising administering to a subject an amount of a zwitterion compound, like HEPES or PIPES, in the compositions set forth.
- Indicators consist of increases in stem cell production, CD 2 , CD 3 , CD 8 and/or CD 20 counts.
- Other markers may include decreased antibody titers, rheumatoid factor (RF), antinuclear antibody (ANA) and anti- acetylcholine antibody.
- Positive changes in certain immunological cell secreted substances include, but are not limited to, cytokines, chemokines, kinases, immunoglobulins and other known biological response modifiers. Improvement is noted in subjects with rheumatoid arthritis and myasthenia gravis. Hemopoietic indicators show positive responses for immunosuppressed and immunodepressed states due to drugs, chemotherapy, radiation, toxins and/or environmental effects. Further positive hemopoietic indicators related to virally induced, immunosuppressed states in addition to cluster determinants and stem cells include P-24 antigen and beta-microglobulin levels. This invention contemplates all of the above embodiments and continues.
- HEPES or other zwitterionic molecules and/or compositions, produces giant platelets and histiocytes in blood demonstrating immune stimulating capability of zwitterionic molecules, and further, shows bone marrow stimulation.
- Zwitterion compounds like HEPES, administered to mammals produces macrocytic invasion of tumors demonstrating antitumor activity.
- the invention further demonstrates that a zwitterionic molecule is shown to be a biological response modifier when HEPES, or other zwitterionic compositions, is used alone or in combination, and administered to the subject, and results in tumor size and/or volume reduction and tumor lysis and/or necrosis.
- Tumor size, volume and necrosis can be detected and monitored by methods utilizing computerized axial tomography (CAT) and/or nuclear magnetic resonance imaging (MRI) and/or nuclear medicine scans, as known to those of skill in the art.
- CAT computerized axial tomography
- MRI nuclear magnetic resonance imaging
- tumors of ectodermal, mesodermal and endodermal origin such as tumors associated with non-Hodgkins lymphoma; adenocarcinoraas, mesothelioma, squamous cell carcinoma; embryonic testicular carcinoma; breast carcinoma; prostate carcinoma; ovarian carcinoma; gall bladder carcinoma, including signet cell type; cholangitic carcinoma; esophageal carcinoma; malignant melanoma; lung carcinoma; hepatoma; multiple myeloma; Kaposi's sarcoma; seminoma; brain tumor, including astrocytoma and glioblastoma, hepatoma, among many others, and further, that the tumor may be primary or metastatic as exemplified by the examples.
- zwitterion compounds provide a method of inducing a diuretic effect in mammals.
- the diuretic effect includes the ability of zwitterionic molecules to effect renal function and effect antidiuretic hormone (ADH) activity.
- ADH antidiuretic hormone
- the ADH method improves respiratory function and/or increases oxygen efficiency and/or improves oxygen-carbon dioxide exchange in lung tissue and includes favorable responses in emphysema, cystic fibrosis and asthma.
- a method of treating autoimmune diseases in a subject comprising administering to the subject an amount of HEPES alone or other zwitterionic molecules in the described compositions such that the progression of the autoimmune pathology and/or pathophysiology of the disease is slowed, stopped or reversed.
- the method can halt wasting, lower antibody titers, increase appetite, improve sleep and increase energy.
- Any autoimmune disease that responds favorably to this method can be treated by this method, such as acquired immunodeficiency syndrome (AIDS); rheumatoid arthritis; myasthenia gravis; psoriasis; glomerulonephritis; thyroiditis; systemic lupus erythromatosis; multiple sclerosis; amyotrophic lateral sclerosis (AML); diabetes; aphthous stomatitis; lichen planus and chronic fatigue syndrome.
- AIDS acquired immunodeficiency syndrome
- rheumatoid arthritis myasthenia gravis
- psoriasis glomerulonephritis
- thyroiditis systemic lupus erythromatosis
- multiple sclerosis am
- the present invention also provides a method of reducing a lesion caused by a virus in a subject, comprising administering an amount of HEPES alone or other zwitterionic molecules in the described compositions, such that the lesion is reduced.
- Preferred methods of composition are as previously described.
- Lesion progression and involvement can be monitored by standard methods known to those of skill in the art, such as, for example, blood tests, antibody titers, measurement of lesions, as well as other evaluation techniques known to those of ordinary skill in the art.
- Lesions produced or induced by any virus that are reduced by this method are included in this invention; as can be tested by the methods herein, such as, for example, Kaposi's sarcoma; herpes simplex; herpes zoster; and genital herpes.
- the invention further provides a method of reducing the intensity and duration of a viral infection in a subject comprising administering to the subject an amount of HEPES or other zwitterionic molecules in the described compositions, such that the intensity and duration of the viral infection are reduced.
- the preferred method of treatment utilizes the methods of compositions previously described.
- the method can be utilized for any viral infection, the intensity and duration of which is reduced by the administration of a composition of the present invention, by the claimed method, as can be tested by the methods herein.
- viral infections are exemplified by the examples and can include, for example, infection by influenza viruses; rotavirus; adeno viruses; herpes viruses; immunodeficiency viruses and coxsackie viruses.
- zwitterion compounds provides a method of effecting changes directly and/or indirectly on serotonin and acetylcholine production and activity.
- the method includes a membrane stabilization effect resulting in antiarrythmagenic effects, antiseizure effects and improved cell survival in trauma or physiologic injury. It results in reduced tissue damage in myocardial infarction and cerebral vascular accidents. Other such effects include reduced nerve cell injury and/or nerve cell repair and/or nerve cell regeneration.
- Pain remission can include remission of pain from a decrease in tumor size and/or volume, or in space-occupying lesions, thus decreasing organ pressure and compression of anatomical structures (i.e. nerves, vessels and other organs), as well as remission of pain not associated with a decrease in tumor size or volume or capsular stretching or a decrease in lesions, such as pain in bones and other pain that occurs before a significant decrease in tumor size or volume or lesion occurs.
- anatomical structures i.e. nerves, vessels and other organs
- Pain reduction may also be due to remission or reduction of inflammatory processes as in rheumatoid arthritis or other inflammatory and/or autoimmune diseases. Pain remission may also be due to changes in other physiologic, pathophysiologic and immune pathophysiologic improvement, such as changes in production of endorphins and similar biochemicals; changes in nervous system activity and changes in ionic conditions and/or membrane permeability and/or membrane stability of a cellular or physiologic pathway levels.
- a method of reducing effects of mental depression in a subject comprising administering to the subject an amount of HEPES alone or other zwitterionic molecules in the described compositions, such that the effects of mental depression are reduced.
- a preferred method of treatment utilizes the methods of compositions as previously described. Effects that are within this invention are those that can be reduced by this method, as can be tested by the methods taught herein and by standard protocols for measuring such effects. Examples of effects which can be reduced by this method include insomnia, weight loss, sadness/melancholy, clinical depression and feelings of isolation. Some results from this method include increased appetite, sense of well being, reduced anxiety, calmness, mood elevation and improved quality of sleep.
- Also provided is a method of treating cancer in a subject comprising administering an amount of HEPES alone or other zwitterionic molecules in the described compositions, such that the progression of cancer is slowed, stopped or reversed.
- a preferred method of treatment utilizes the methods of compositions as previously described. Cancers included in this method are those which are reduced by this method as can be tested given the teachings herein. Some examples of such cancers include breast cancer; prostate cancer; non-Hodgkins lymphoma; cholangitic cancer (including signet cell type); glioblastoma; and others as previously stated.
- the cancers may be primary or metastatic. They include all cancers of ectodermal, mesodermal and endodermal origin.
- the invention comprises a method of improving visual color perception, increased visual acuity, improved depth perception, improved hearing and improved taste. Other cellular effects include promotion of hair growth.
- the method includes treating toxic syndromes, such as Gulf War Syndrome and/or Agent Orange toxicity and/or other such syndromes that are related to organic phosphate induced disease, disease strands and/or polyneuropathies.
- hepatitis in a subject comprising administering to the subject an amount of HEPES alone or other zwitterionic molecules in the described compositions, such that the pathologic and pathophysiologic activity of hepatitis is reduced.
- pathologic and pathophysiologic activities that are reduced by this method include, for example, elevated bilirubin levels and hepato-spleno- perennialy.
- a preferred method of the treatment utilizes the methods of composition previously described.
- hepatitis it is meant to include, for example, hepatitis A, hepatitis B, hepatitis C (formerly non-A, non-B) and alcoholic hepatitis.
- Also provided herein is a method of reducing side effects of chemotherapy and radiation therapy in a subject comprising administering to the subject an amount of HEPES alone or other zwitterionic molecules in the described compositions, such that the side effects of chemotherapy and radiation therapy are reduced.
- a preferred method of treatment utilizes the compositions previously described. Side effects which can be reduced included nausea, vomiting and hair loss.
- amphoteric zwitterionic compound also has been demonstrated to produce antispasmodic effects (affects muscle, smooth and striated) activity and promotes hair growth in animals.
- the invention also comprises a method of treating blood coagulation disorders in effecting changes in fibrin and fibrinogen activity.
- pathologic activities include, for example, hypercoagulable states and/or hypocoagulable as may be seen in genetic disorders and/or certain pathophysiologic states, including sepsis and/or drug induced coagulation disorders and/or other metabolic disturbances.
- the present invention also provides a method of detecting infection in a subject comprising administering HEPES alone or other zwitterionic molecules in the described compositions to the subject and monitoring development at a reaction, such as fever, chills, diaphoresis and/or rigor by the subject, such development indicating presence of infection in the subject.
- a rapid search for infection can be accomplished whether such infection is clinical or sub- clinical with the etiology being bacterial, fungal or viral. It is further contemplated that the reactions of fever, chills and rigor may be immunologically mediated and therefore in vitro testing for immunological substances using controls against the subjects blood and/or cells would be developed. This may include measurement of cytokines (possibly IL-l or others), chemokines, kinases and other cell-secreted products.
- a method for treating Alzheimer's disease, senile dementia and Creutzfeldt-Jakob disease, in a subject comprising administering to the subject an amount of HEPES alone or other zwitterionic molecules in the described compositions, such that the pathologic and/or pathophysiologic activities are slowed and/or reversed.
- pathologic or pathophysiologic activities that are slowed or reversed by this method include, for example, improved memory, improved coordination, decreased agitation and improved quality of life.
- a preferred method of the treatment utilizes methods of composition previously described.
- compositions may be administered parenterally; e.g. sublingually, intrathecally, intravenously, intramuscularly; subcutaneously, and the like. Oral preparations and topical preparations are shown to be effective.
- the exact amount of a composition required will vary from subject to subject, depending upon species, age, weight, general condition of the subject, the severity of the disease that is being treated, the mode of administration used and the like. Thus, it is not possible to state an exact amount.
- dosages of lOOOmg, or more, in compositions described may be given intravenously daily. Dosages of 35 grams intravenously daily have been given with responses noted in some diseases. There have been complaints of headache and fatigue in a few subjects at higher dosages ( ⁇ 10%).
- Toxicity studies have shown no toxic effects at 500mg/kg response levels for each disease. Dosage may vary from less than .01mg/kg to greater than 1 gram/kg daily intravenously, orally, sublingually, intrathecally or topically. Length of therapy is yet to be determined.
- compositions can be in pharmaceutical compositions in solid, semi-solid or liquid forms.
- the total effect of a biological response modifier depends upon many variables, including compositions which as described may have increased effects depending upon type of disease and pharmaceutical form.
- compositions may have HEPES alone or other zwitterionic molecules alone or with mammalian serum or with supernatants or supernatant fractions, filtered or unfiltered, each having different bioactivity and biological response modifier capability on different disorders and diseases.
- the composition may be provided with pharmaceutically acceptable carriers and, in addition, may include any other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc., that do not interfere with the activity of the composition, for example, saline solutions.
- the present invention is more particularly described in the following examples which are intended as illustrative only, since numerous modifications and variations therein will be apparent to those skilled in the art.
- the zwitterionic molecular compounds useful in treatment many vary in effective, therapeutic concentrations depending upon the disease and condition of the mammal. However, generally effective, therapeutic concentrations range from about a low of O.OOlmg/kg to as high as 5000mg/kg, such as to 500mg/kg, or more.
- Various dose response ranges are, for example, but not limited to: for reduction in pain of lmg/kg to 20mg/kg; and for generation of platlets, antieffect and immune stimulatory effects of over lOmg/kg, such as 20mg/kg to lOOmg/kg.
- the zwitterion compounds are used alone or in combination with other representative pharmaceutical carrier compounds, like saline solution bulking agents, stabilizers, inert ingredients, or other active ingredients, such as amino acid compounds, like, but not limited to, carbohydrate amines, like L- glutamine, in varying amounts, for example, of O.Olmg/kg to 1 gram/kg.
- other representative pharmaceutical carrier compounds like saline solution bulking agents, stabilizers, inert ingredients, or other active ingredients, such as amino acid compounds, like, but not limited to, carbohydrate amines, like L- glutamine, in varying amounts, for example, of O.Olmg/kg to 1 gram/kg.
- amino acids for use with HEPES include L- alanine; L-Araline HCl; L-Asparagine-H 2 0; L-Aspartic Acid; L- Cystine-2HC1; L-Glutamic Acid; Glycine; L-Hstidine-HCl-H 2 0; L-Isoleucine; L-Leucine; L-Lysine-HCl; L-Methionine; L- Phenylalanine; L-Proline; L-Serine; L-Tryptophan; L- Tyrosine-2Na; L-Valine; as well as vitamins including d- Biotin; D-Ca Pantothenate; Choline Chloride; Folic Acid; i- Inositol; Nicotinamide; Pyridoxine-HCl; Riboflavin; Thia ine-HCl and Vitamin B i2 .
- the zwitterion molecular compositions are employed in sterile liquid form in saline solutions, such as in syringes or intravenous containers or bags, and contain a buffer agent, such as phosphate or bicarbonate or other buffers, like sodium and potassium, in saline solution.
- saline solutions such as in syringes or intravenous containers or bags
- a buffer agent such as phosphate or bicarbonate or other buffers, like sodium and potassium
- Piperazine zwitterion compounds of the invention include zwitterion piperazine compounds with an hydroxyl and a sulfonic acid group like those compounds having the structural formula:
- R x is an N-linking group, like an alkyl group, such as Ci-C ⁇ alkyl
- R 2 is an hydroxyl or amine
- R 3 is an N-liking group, like an alkane, such as C -C 6
- R 4 is an acid or substituted acid, like citrate, adipic, carboxylic (COOH); phosphoric (P0 4 OH) or sulfonic (S0 2 0H) acid and the salts of the zwitterion compound.
- compositions also useful contain human serum in effective and carrier amounts, like A, O, B and particularly, AB human serum certified to be negative for bacteria, mycoplasma, hepatitis, TB, HTLVI AND II, and other infectious agents or components.
- human serum in effective and carrier amounts, like A, O, B and particularly, AB human serum certified to be negative for bacteria, mycoplasma, hepatitis, TB, HTLVI AND II, and other infectious agents or components.
- Type A 100-300mg HEPES ultra pure 1.6cc L-glutamine
- Normal administration was in 50cc normal saline (0.9% saline solution) given intravenously over 15-30 minutes.
- the patient was given a composition of 300mg HEPES, lcc human serum, 1 ml L-glutamine with amino acids and bicarbonate combined with a human cell culture supernatant (intravenously with normal saline) daily for one month.
- a human cell culture supernatant intravenously with normal saline
- CEA carcinogenic embryonic antigen
- the patient was given 300mg HEPES, .8 cc human serum, 1.6cc L-glutamine with amino acids (no culture supernatant) intravenously in 50cc normal saline daily for four weeks. After four weeks, his CEA level fell to 600. His liver function SGOT, SGPT and LDH were normal. Alkaline phosphatase was ⁇ 200. He was essentially pain free. He could take liquids and soft solids. Subject Four
- Kaposi's sarcoma is a virally-mediated tumor.
- zwitterionic compounds such as HEPES
- HEPES zwitterionic compounds
- concentrations of approximately 12mg/kg the effect appears to start, while at concentrations in excess of lOOmg/kg to 500mg/kg or greater, baseline levels of alkaline phosphatase fall by a factor of two or greater, and in some cases it is not measurable by standard laboratory methods.
- five healthy canines were administered up to 500mg/kg of HEPES. At these doses, serum alkaline phosphatase was not detected by standard laboratory methods in all canines.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU19577/97A AU700502B2 (en) | 1996-02-13 | 1997-02-13 | Zwitterionic compositions and methods as biological response modifiers |
EA199800717A EA001929B1 (en) | 1996-02-13 | 1997-02-13 | Method of treating a disease in a mammal and zwitterionic composition |
US08/983,269 US6071919A (en) | 1996-02-13 | 1997-02-13 | Zwitterionic compositions and methods as biological response modifiers |
EP97907616A EP0904073A4 (en) | 1996-02-13 | 1997-02-13 | Zwitterionic compositions and methods as biological response modifiers |
JP52947997A JP3309990B2 (en) | 1996-02-13 | 1997-02-13 | Compositions and methods of zwitterions as biological response modifiers |
IL12577597A IL125775A (en) | 1996-02-13 | 1997-02-13 | Use of a zwitterion composition in the preparation of pharmaceutical compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/600,901 US5716959A (en) | 1996-02-13 | 1996-02-13 | Method of treating disease with piperazine zwitterion compounds |
US08/600,901 | 1996-02-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997029745A1 true WO1997029745A1 (en) | 1997-08-21 |
WO1997029745B1 WO1997029745B1 (en) | 1997-09-25 |
Family
ID=24405525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/002270 WO1997029745A1 (en) | 1996-02-13 | 1997-02-13 | Zwitterionic compositions and methods as biological response modifiers |
Country Status (8)
Country | Link |
---|---|
US (2) | US5716959A (en) |
EP (1) | EP0904073A4 (en) |
JP (1) | JP3309990B2 (en) |
AU (1) | AU700502B2 (en) |
CA (1) | CA2230639A1 (en) |
EA (1) | EA001929B1 (en) |
IL (1) | IL125775A (en) |
WO (1) | WO1997029745A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140378467A1 (en) * | 2009-09-17 | 2014-12-25 | North Texas Medical Associates | Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448251B1 (en) * | 1997-11-28 | 2002-09-10 | Peter T. Pugliese | Zwitterionic-fatty acid compounds having anti-inflammatory properties |
US6114337A (en) * | 1998-11-27 | 2000-09-05 | Pugliese; Peter T. | Zwitteronic-fatty acid compounds having anti-inflammatory properties |
WO1999027791A1 (en) | 1997-11-28 | 1999-06-10 | Pugliese Peter T | Zwitterionic fatty acid compounds for anti-inflamation |
EP1140112B1 (en) * | 1998-12-21 | 2005-03-09 | Inkeysa, S.A. | Etherlysophospholipids for the treatment of chronic inflammatory diseases |
CA2374003C (en) * | 1999-05-17 | 2008-02-12 | Aesgen, Inc. | Improved cellular uptake of bioactive agents |
AUPR626001A0 (en) * | 2001-07-10 | 2001-08-02 | Mcgregor, Neil | A method of treatment and/or prophylaxis |
CN1802152A (en) * | 2002-08-01 | 2006-07-12 | 艾斯根公司 | Improved treatment of cancer with glutamine |
US7592154B2 (en) * | 2005-08-05 | 2009-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating SOS response induction by antimicrobial agents |
SI22466A (en) * | 2007-03-14 | 2008-10-31 | Romina Znoj | Combination containing plant extracts and its use for treatment of various forms of cancer |
WO2010143188A2 (en) * | 2009-06-09 | 2010-12-16 | Mardi Medicines Ltd. | Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms |
AU2016228315B2 (en) * | 2009-09-17 | 2018-01-04 | Bespoke Bioscience, Llc | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
AU2014206220B2 (en) * | 2009-09-17 | 2016-09-29 | Bespoke Bioscience, Llc | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
US20140377814A1 (en) * | 2012-02-07 | 2014-12-25 | Industry-Academic Cooperation Foundation, Yonsei University | Method For The Fixation Or Conversion Of High-Pressure Carbon Dioxide Using Barophilic Sulfur-Oxidizing Chemolithoautotrophs |
JP6612004B1 (en) * | 2018-07-31 | 2019-11-27 | 株式会社親広産業 | Glucose consumption promoter and glycolysis promoter |
WO2020026471A1 (en) * | 2018-07-31 | 2020-02-06 | 株式会社親広産業 | Glucose consumption promoter and glycolysis promoter |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100827B1 (en) * | 1982-08-17 | 1986-09-03 | Rosical Limited | Pharmaceutical composition containing an aliphatic aminosulphonic acid |
US4696917A (en) * | 1985-08-01 | 1987-09-29 | Lindstrom Richard L | Irrigation solution |
IE853206L (en) * | 1985-12-18 | 1987-06-18 | Sullivan Donncha O | Use of aminosulfonic acids in treatment of inflammatory¹conditions |
GB8713091D0 (en) * | 1987-06-04 | 1987-07-08 | Millrine W P | Pharmaceutical compositions |
AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
AU9805998A (en) * | 1997-10-15 | 1999-05-03 | T. Ronald Theodore | Zwitterionic compositions and methods as biological response modifiers |
WO1999027791A1 (en) * | 1997-11-28 | 1999-06-10 | Pugliese Peter T | Zwitterionic fatty acid compounds for anti-inflamation |
-
1996
- 1996-02-13 US US08/600,901 patent/US5716959A/en not_active Expired - Fee Related
-
1997
- 1997-02-13 EA EA199800717A patent/EA001929B1/en not_active IP Right Cessation
- 1997-02-13 WO PCT/US1997/002270 patent/WO1997029745A1/en not_active Application Discontinuation
- 1997-02-13 IL IL12577597A patent/IL125775A/en not_active IP Right Cessation
- 1997-02-13 CA CA002230639A patent/CA2230639A1/en not_active Abandoned
- 1997-02-13 US US08/983,269 patent/US6071919A/en not_active Expired - Fee Related
- 1997-02-13 EP EP97907616A patent/EP0904073A4/en not_active Withdrawn
- 1997-02-13 AU AU19577/97A patent/AU700502B2/en not_active Ceased
- 1997-02-13 JP JP52947997A patent/JP3309990B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
STAPLETON P P, ET AL.: "EFFECTS OF IN-VIVO ADMINISTRATION OF TAURINE AND HEPES ON THE INFLAMMATORY RESPONSE IN RATS", JOURNAL OF PHARMACY AND PHARMACOLOGY, JOHN WILEY & SONS LTD, LONDON; GB, vol. 46, no. 09, 1 September 1994 (1994-09-01), LONDON; GB, pages 745 - 750, XP002947886, ISSN: 0022-3573 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140378467A1 (en) * | 2009-09-17 | 2014-12-25 | North Texas Medical Associates | Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury |
US9867820B2 (en) | 2009-09-17 | 2018-01-16 | Bespoke Bioscience, Llc | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
US10213425B2 (en) | 2009-09-17 | 2019-02-26 | Bespoke Bioscience, Llc | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
US20190142825A1 (en) * | 2009-09-17 | 2019-05-16 | Bespoke Bioscience, Llc | Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury |
IL264055B1 (en) * | 2009-09-17 | 2024-05-01 | Bespoke Bioscience Llc | N-2-hydroxy-ethyl-piperazine-n’-2-ethane sulfonic acid (hepes) for treating post-chemotherapy cognitive impairment induced by demyelination |
Also Published As
Publication number | Publication date |
---|---|
IL125775A (en) | 2001-08-08 |
JPH11504050A (en) | 1999-04-06 |
IL125775A0 (en) | 1999-04-11 |
US6071919A (en) | 2000-06-06 |
EP0904073A1 (en) | 1999-03-31 |
US5716959A (en) | 1998-02-10 |
AU1957797A (en) | 1997-09-02 |
EA001929B1 (en) | 2001-10-22 |
JP3309990B2 (en) | 2002-07-29 |
AU700502B2 (en) | 1999-01-07 |
CA2230639A1 (en) | 1997-08-21 |
EA199800717A1 (en) | 1999-02-25 |
EP0904073A4 (en) | 2001-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU700502B2 (en) | Zwitterionic compositions and methods as biological response modifiers | |
Redlich et al. | IL-11 enhances survival and decreases TNF production after radiation-induced thoracic injury. | |
TWI306028B (en) | A combination comprising combretastatin and anticancer agnets | |
EP1369119B1 (en) | Il-12 expression controlling agents | |
JP2005008534A (en) | Anticancer agent and method for treating cancer | |
EP0679081B1 (en) | Pharmaceutical compositions for prevention and treatment of cancerous disease and process for their preparation | |
RU2008105603A (en) | TREATMENT OF CANCER WITH THE USE OF VIRUSES, FLUORPYRIMIDINES AND CAMPTOTECINS | |
KR20080071182A (en) | Salts of 9-oxoacridine-10-acetic acid with 1-alkylamino-1-desoxy-polyols | |
US20050080122A1 (en) | Anti-viral compounds | |
AU2003202298A1 (en) | Anti-viral compounds | |
Poydock et al. | Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumors | |
JP2001504085A (en) | Pharmaceutical compositions containing tyrphostin | |
US4384001A (en) | Treatment of tumors with thiazolidine-4-carboxylic acid | |
CN111214475B (en) | Combined pharmaceutical composition for resisting double-hit lymphoma and application thereof | |
Krahenbuhl et al. | Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells. | |
JPS6236331A (en) | Anti-infective agent and immunological activator | |
Reiner et al. | Increased Growth of Tumor Isotransplants After Immunosuppression of the Recipient Mice by Methotrexate or 5-Fluoro-2′-Deoxyuridine | |
WO1999018964A1 (en) | Zwitterionic compositions and methods as biological response modifiers | |
JP2610621B2 (en) | 15-Deoxyspergualin-containing drug | |
GATANAGA et al. | Combination antitumor therapy with rabbit tumor necrosis factor and chemo-and immuno-therapeutic agents against murine tumors | |
Rizzo et al. | Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma | |
MXPA98006518A (en) | Zwitterionic compositions and methods as modifiers of biological response | |
Schultz et al. | Potentiation of nonspecific immunotherapy of experimental lung metastases by indomethacin | |
JPH07503705A (en) | Pharmaceutical lysine-containing polypeptide compositions and methods of use thereof | |
JPS63501422A (en) | How to treat genital and oral herpes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN IL JP KR MX NO NZ SG US AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2230639 Country of ref document: CA Ref document number: 2230639 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1998/006518 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1997 529479 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997907616 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199800717 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08983269 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997907616 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997907616 Country of ref document: EP |